Search - tctmd.com

Displaying 61 - 80 of 98

Sort: Relevancy | Date

News Conference News ESC 2021

GUIDE-HF: Pulmonary Artery Sensor May Help in Mild HF, but COVID-19 Muddies Water

Shelley Wood

August 27, 2021

News Opinion Editor's Corner ESC 2021

ESC 2021: Trials, Guidelines, and Channel Surfing at This Year’s Virtual Congress

Shelley Wood

August 19, 2021

News Conference News ESC 2020

COVID-19 Blamed for Weaker Research Published by Top-Tier Journals in 2020

Michael O'Riordan

September 04, 2020

News Conference News ESC 2020

Revascularization Benefits ISCHEMIA Patients With Mild LV Dysfunction or HF

Michael O'Riordan

August 31, 2020

News Conference News ESC 2020

PARALLAX: Mixed Results for Sacubitril/Valsartan in HFpEF

Todd Neale

August 30, 2020

News Conference News ESC 2020

EXPLORER-HCM: Mavacamten Improves Exercise Capacity and Functional Class

Michael O'Riordan

August 29, 2020

News Conference News ESC 2020

EMPEROR-Reduced: Empagliflozin Cuts Hospitalizations, CV Mortality in HFrEF

Michael O'Riordan

August 28, 2020

News Conference News ESC 2020

More Than Half of Patients See a GP in the 2 Weeks Before OHCA

Yael L. Maxwell

August 28, 2020

News Conference News ESC 2019

Primary Prevention ICDs Still Render Better Survival, Even in Modern HFrEF Patients

Todd Neale

September 13, 2019

News Conference News ESC 2019

Beta-blockers Safe, Effective for HFrEF Patients With Renal Dysfunction: Meta-analysis

Yael L. Maxwell

September 12, 2019

$Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction Primary results of the PARAGON-HF trial$

Presentation ESC 2019

Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction Primary Results of the PARAGON-HF Trial

Presenter: Scott D. Solomon

September 01, 2019

News Conference News ESC 2019

DAPA-HF Details: Dapagliflozin Slashes HF Outcomes, Even in Nondiabetics

Shelley Wood

September 01, 2019

News Conference News ESC 2019

PARAGON-HF Misses Primary Endpoint, but Hints of Benefit Seen

Todd Neale

September 01, 2019

News Conference News ESC 2019

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

Shelley Wood

August 22, 2019

News Conference News ESC 2018

My Takeaways From ESC 2018: Good or Bad, the Luxury of New Data Begets Cries for More

Shelley Wood

September 14, 2018

News Conference News ESC 2018

New ESC/EACTS Revascularization Guidelines Make Room for Radial First, STICH, and DES for All

Michael O'Riordan

August 29, 2018

Medically Ill Pa+ent Assessment of Rivaroxaban Versus Placebo IN Reducing Post-Discharge Venous Thrombo-Embolism Risk (MARINER) Trial: Primary Results

Presentation ESC 2018

Medically Ill Patient Assessment of Rivaroxaban Versus Placebo IN Reducing Post-Discharge Venous Thrombo-Embolism Risk (MARINER) Trial: Primary Results

Presenter: Alex C. Spyropoulos

August 27, 2018

News Conference News ESC 2018

Tafamidis, a Transthyretin Stabilizer, Offers Hope for Rare Cardiomyopathy

Michael O'Riordan

August 27, 2018

News Conference News ESC 2018

COMMANDER HF: Low-Dose Rivaroxaban Flops in Heart Failure

Todd Neale

August 27, 2018

News Conference News ESC 2018

MITRA-FR: No Benefit of MitraClip in Functional MR

Shelley Wood

August 27, 2018

Advertisement

GUIDE-HF: Pulmonary Artery Sensor May Help in Mild HF, but COVID-19 Muddies Water

ESC 2021: Trials, Guidelines, and Channel Surfing at This Year’s Virtual Congress

COVID-19 Blamed for Weaker Research Published by Top-Tier Journals in 2020

Revascularization Benefits ISCHEMIA Patients With Mild LV Dysfunction or HF

PARALLAX: Mixed Results for Sacubitril/Valsartan in HFpEF

EXPLORER-HCM: Mavacamten Improves Exercise Capacity and Functional Class

EMPEROR-Reduced: Empagliflozin Cuts Hospitalizations, CV Mortality in HFrEF

More Than Half of Patients See a GP in the 2 Weeks Before OHCA

Primary Prevention ICDs Still Render Better Survival, Even in Modern HFrEF Patients

Beta-blockers Safe, Effective for HFrEF Patients With Renal Dysfunction: Meta-analysis

Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction Primary Results of the PARAGON-HF Trial

DAPA-HF Details: Dapagliflozin Slashes HF Outcomes, Even in Nondiabetics

PARAGON-HF Misses Primary Endpoint, but Hints of Benefit Seen

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

My Takeaways From ESC 2018: Good or Bad, the Luxury of New Data Begets Cries for More

New ESC/EACTS Revascularization Guidelines Make Room for Radial First, STICH, and DES for All

Medically Ill Patient Assessment of Rivaroxaban Versus Placebo IN Reducing Post-Discharge Venous Thrombo-Embolism Risk (MARINER) Trial: Primary Results

Tafamidis, a Transthyretin Stabilizer, Offers Hope for Rare Cardiomyopathy

COMMANDER HF: Low-Dose Rivaroxaban Flops in Heart Failure

MITRA-FR: No Benefit of MitraClip in Functional MR

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content